Equities

Bioxyne Ltd

Bioxyne Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.007
  • Today's Change-0.001 / -12.50%
  • Shares traded241.83k
  • 1 Year change-68.18%
  • Beta1.4089
Data delayed at least 20 minutes, as of Apr 24 2024 03:12 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bioxyne Limited is an Australia-based health and wellness products company. Its activity is the development, manufacture and distribution of nutritional health and wellness supplements through indirect wholesale and direct sales channels in the health and wellness sector. It is engaged in the consumer dietary supplements and functional foods markets through its probiotic, Lactobacillus fermentum VRI-003 (PCC). The Company has developed a range of functional food and beauty products containing ingredients sourced primarily from New Zealand, through its direct sales business trading as Bioxyne International. It has an interest in Breathe Life Sciences (BLS). It has operations across Australia, the United Kingdom, Japan, Europe and Southeast Asia with a health and wellness product portfolio, including health supplements, skincare, probiotics, cannabis-derived raw materials, starting materials, active pharmaceutical ingredients, cannabinoid-based therapies and telemedicine technology.

  • Revenue in AUD (TTM)8.65m
  • Net income in AUD-14.17m
  • Incorporated1998
  • Employees16.00
  • Location
    Bioxyne LtdSuite 506, Level 5, 50 Clarence StreetSYDNEY 2000AustraliaAUS
  • Phone+61 29078-8180
  • Fax+61 29078-7661
  • Websitehttps://bioxyne.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Tissue Repair Ltd457.52k-3.28m12.84m----0.8075--28.06-0.0542-0.05420.00760.28480.0209--7.95---14.96---15.46--98.19---716.30--25.84--0.00------38.95------
BTC Health Ltd16.03k-8.26m13.94m1.00--2.578.44869.45-0.0305-0.03050.000050.01670.0017--0.031---89.67-23.15-91.36-24.64-----51,522.02-2,498.18---0.07870.00---86.04-26.76-1,665.01------
Vectus Biosystems Ltd86.39k-2.49m14.63m----6.18--169.38-0.0467-0.04670.00160.04450.0191-------54.95-96.22-68.14-691.17-----2,880.80-27,693.78---439.760.00--69,287.5097.8713.64------
Medlab Clinical Ltd1.47m-8.92m15.07m14.00------10.26-3.91-3.910.64331.430.138.898.33---79.66-48.84-107.17-59.5182.8254.18-612.90-242.171.56-141.990.2222--75.10-21.4812.89---15.58--
Adalta Ltd3.56m-5.04m15.25m----6.30--4.28-0.0129-0.01290.00920.00460.5491--4.72---77.76-67.77-195.09-103.16-----141.60-160.72---57.860.4533--28.1811.1719.96---7.47--
Avecho Biotechnology Ltd473.55k-3.44m15.85m29.00--1.99--26.77-0.0016-0.00160.00020.0020.08882.070.5132---64.45-47.08-75.73-55.25-9.2578.67-725.70-156.438.19--0.0267---58.07-19.42-46.71------
Amplia Therapeutics Ltd1.87m-4.46m16.30m1.00--0.866--9.30-0.0224-0.02240.00940.07390.0949--0.7018---22.64-25.27-26.24-26.78-----238.69-342.26----0.1318---42.1012.31-71.30--31.88--
Bioxyne Ltd8.65m-14.17m16.37m16.00--4.60--1.66-0.0074-0.00740.00440.00151.836.1210.50---302.23-22.07-418.10-28.5038.3045.13-165.04-39.691.50--0.00--1,013.0520.97-292.69---19.86--
Algorae Pharmaceuticals Ltd84.10k-2.25m16.61m----4.66--200.52-0.0015-0.00150.000060.00220.0245--1.79---65.51-46.12-70.91-53.52-----2,678.04-591.05---136.750.00--1,132.26-44.06-7.68------
Nyrada Inc3.08m-4.98m17.58m----3.27--5.59-0.0319-0.03190.01980.02940.3983-------64.37-64.90-71.93-84.66-----161.62-380.62---15,086.390.00--42.54229.09-96.52------
Noxopharm Ltd3.90m-12.13m17.83m1.00k--2.71--4.57-0.0415-0.04150.01340.02250.2684--1.643,901.84-83.43-50.96-94.78-62.98-----310.82-191.70---1.470.00--11.3244.0219.34------
Auscann Group Holdings Ltd2.05m-9.44m18.27m27.00------8.86-0.0213-0.02170.00430.01620.1674--5.35---77.15-39.85-78.72-40.73100.59---460.74-925.91---23.160.00--13.8851.3757.10------
Patrys Ltd1.70m-5.12m18.52m15.00--3.69--10.92-0.0025-0.00250.00080.00240.1978--0.5828---59.77-43.96-68.99-47.06-----302.26-230.44----0.00---14.4540.52-4.15------
Acrux Ltd14.46m-709.00k18.61m43.00--3.13--1.23-0.0024-0.00240.05020.01951.29--4.86---6.34-39.91-9.21-46.0072.38---4.90-132.53----0.2861--133.7428.2992.23---16.66--
LTR Pharma Ltd-100.00bn-100.00bn19.01m----5.99----------0.0451----------------------------0.00---100.00---41.65------
Argent BioPharma Ltd1.32m-17.02m19.24m----10.90--13.85-3.32-3.320.10030.03720.08130.70781.58---105.32-111.29-345.98-171.0521.8732.52-1,295.20-632.420.6561-24.850.4104---28.4147.31-2.34---16.20--
Data as of Apr 24 2024. Currency figures normalised to Bioxyne Ltd's reporting currency: Australian Dollar AUD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.